COPD合并呼衰患者应用小剂量甲泼尼龙琥珀酸钠联合尼可刹米治疗的临床研究

A Clinical Study of Low-dose Methylprednisolone Sodium Succinate Combined with Nicochamide in The Treatment of COPD Patients with Respiratory Failure

目的探讨小剂量甲泼尼龙琥珀酸钠联合尼可刹米治疗慢性阻塞性肺疾病(COPD)合并呼衰的临床应用效果及对患者肺功能的影响。方法102例研究对象选自我院2021年1月至2022年1月收治的COPD合并呼吸衰竭患者,依据随机数字表法分为对照组(常规治疗联合尼可刹米)、观察组(对照组联合甲泼尼龙琥珀酸钠),各51例。结果与对照组相比较,观察组患者临床治疗总有效率更高,与治疗前比,治疗后观察组与对照组肺动脉压、PaCO_(2)、心率、呼吸均呈现降低趋势,且前者更低,FEV1%、FEV1/FVC、PaO_(2)、血氧饱和度水平均呈现上升趋势,其中观察组比对照组高,与对照组相比较,观察组治疗期间的不良反应发生率更低(P<0.05)。结论小剂量甲泼尼龙琥珀酸钠联合尼可刹米可以改善COPD合并呼衰患者肺功能、心率、呼吸状况和血氧饱和度,降低不良反应的发生率,且疗效显著。

Objective To investigate the clinical effect of low-dose methylprednisolone sodium succinate combined with nicotamide in the treatment of chronic obstructive pulmonary disease(COPD)patients with respiratory failure.Methods A total of 102 patients with COPD combined with respiratory failure were selected from January 2021 to January 2022 in our hospital.They were randomly divided into a control group(routine treatment combined with nikethamide)and an observation group(control group combined with methylprednisolone sodium succinate),51 cases in each group.Results Compared with the control group,the total effective rate of clinical treatment was higher in the observation group.Compared with that before treatment,the pulmonary artery pressure,PaCO_(2),heart rate and respiration of the two groups decreased after treatment,which was lower than that of the control group.The levels of FEV1,FEV1/FVC,PaO_(2) and oxyhemoglobin saturation all increased in the observation group,which was higher than that of the control group.Compared with the control group,the incidence of adverse reactions during treatment was lower in the observation group(P<0.05).Conclusion Low-dose methylprednisolone sodium succinate combined with nicotinamide can improve lung function,heart rate,respiratory status and blood oxygen saturation in patients with COPD and respiratory failure,reduce the incidence of adverse reactions,and has a significant effect.